article thumbnail

The Society of Thoracic Surgeons Launches New Valve Surgery Risk Calculators

DAIC

Tricuspid Valve Repair Existing literature on national surgical outcomes of isolated tricuspid valve repair or replacement is based on data from over a decade ago and may not reflect current practice results. Analysis of 13,587 patients undergoing isolated tricuspid valve surgery from 2017 to 2023 revealed a 5.5%

TAVR 111
article thumbnail

SAVR’s Value in the TAVR Era

CardiacWire

Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates. The post SAVR’s Value in the TAVR Era appeared first on Cardiac Wire.

TAVR 69
article thumbnail

TCT 2024’s Top TAVR Studies

CardiacWire

This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Patients who received early TAVR were 16% less likely to experience MACE and saw better heart function over a median of 3.8

TAVR 59
article thumbnail

Greater Baseline TR Associated With Worse Outcomes After TAVR or Mitral TEER

American College of Cardiology

Patients with moderate or severe tricuspid regurgitation (TR) prior to undergoing TAVR or mitral transcatheter edge-to-edge repair (TEER), when compared to patients with no or mild TR, were associated with worse health status and clinical outcomes, according to a study published in JACC: Cardiovascular Interventions.

TAVR 51
article thumbnail

Edwards Lifesciences to Sell Critical Care to BD

DAIC

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.

article thumbnail

Early-Stage Results with Transcatheter Tricuspid-Valve Replacement

The New England Journal of Medicine

Transcatheter aortic-valve replacement (TAVR) has been accepted as a reasonable alternative to surgical aortic-valve replacement for the treatment of.

article thumbnail

FDA Approves TriClip; Fortified Eggs vs Cholesterol; Impella Maker Chided

Med Page Today

(MedPage Today) -- Abbott said its TriClip transcatheter edge-to-edge repair system snagged FDA approval for treating for tricuspid regurgitation. Medtronic announced that the FDA approved the Evolut FX+ TAVR system, featuring a larger diamond.